Cerebral Small Vessel Disease in Immune-Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission - Scorecard - MDSpire
Clinical Scorecard: Cerebral Small Vessel Disease in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura During Acute Episodes and Remission Phases
At a Glance
Category
Detail
Condition
Cerebral Small Vessel Disease (cSVD)
Key Mechanisms
Involves pathologies of small perforating arterioles, capillaries, and venules leading to ischemic strokes and cognitive impairment.
Target Population
Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP).
Care Setting
Hospitalized patients undergoing MRI for acute iTTP.
Key Highlights
cSVD is prevalent in approximately 60% of iTTP cases, leading to neurological impairment.
MRI findings are critical for diagnosing cSVD, including white matter hyperintensities and cerebral microbleeds.
Each increment in total cSVD score increases the risk of subsequent stroke and dementia.
Guideline-Based Recommendations
Diagnosis
MRI is the principal basis for diagnosing cSVD using STRIVE criteria.
Management
Monitor ADAMTS13 activity and anti-ADAMTS13 antibodies throughout follow-up.
Monitoring & Follow-up
Routine activity measurements every 3 months after achieving laboratory remission.
Risks
Higher total cSVD scores correlate with increased risk of stroke, dementia, and all-cause mortality.
Patient & Prescribing Data
Adults hospitalized for acute iTTP.
Caplacizumab treatment is monitored with weekly ADAMTS13 activity assessments.
Clinical Best Practices
Conduct brain MRI during acute iTTP episodes and follow-up at 12–18 months.
Assess neurological signs and symptoms retrospectively from hospital discharge summaries.
by Addolorata Truma, Francesco Maria Lo Russo, Giorgio Conte, Ilaria Mancini, Andrea Artoni, Juri Alessandro Giannotta, Barbara Ferrari, Pasquale Agosti, Maria Abbattista, Matteo Gagliardi, Eleonora Piccin, Marco Stroppi, Fabio Maria Triulzi, Flora Peyvandi
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
